宏源药业
(301246)
| 流通市值：57.04亿 | | | 总市值：134.16亿 |
| 流通股本：1.70亿 | | | 总股本：4.00亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 703,525,713.02 | 1,939,468,837.26 | 1,317,076,113.48 | 882,558,988.14 |
| 营业收入 | 703,525,713.02 | 1,939,468,837.26 | 1,317,076,113.48 | 882,558,988.14 |
| 二、营业总成本 | 543,865,867.35 | 1,794,917,960.56 | 1,292,835,287.81 | 865,650,935.27 |
| 营业成本 | 478,380,974.86 | 1,575,318,540.94 | 1,149,650,892.3 | 767,049,606.04 |
| 税金及附加 | 4,657,198.23 | 15,235,073.96 | 9,121,199.39 | 6,034,293.09 |
| 销售费用 | 11,851,769.06 | 47,628,250.54 | 33,164,828.15 | 21,924,338.62 |
| 管理费用 | 16,089,211.33 | 62,596,758.45 | 38,703,192.73 | 27,945,888.46 |
| 研发费用 | 29,342,302.03 | 83,900,358.56 | 55,846,719.9 | 39,589,553.45 |
| 财务费用 | 3,544,411.84 | 10,238,978.11 | 6,348,455.34 | 3,107,255.61 |
| 其中:利息费用 | 2,579,508.97 | 13,787,037.92 | 6,880,196.05 | 6,880,196.05 |
| 其中:利息收入 | 1,118,067.66 | 6,556,054.12 | 3,897,184.37 | 3,897,184.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,469,910.38 | 1,849,195.72 | 1,832,003.54 | 812,583.52 |
| 加:投资收益 | 23,263,185.41 | 31,064,704.62 | -1,521,506.2 | 63,026.25 |
| 资产处置收益 | -1,155,325.07 | 773,836.31 | 723,042.49 | 67,192.75 |
| 资产减值损失(新) | -3,805,823.46 | -40,087,507.9 | -28,988,134.13 | -23,976,610.81 |
| 信用减值损失(新) | -3,625,152.46 | -3,500,781.59 | -2,637,648.45 | -2,077,677.6 |
| 其他收益 | 7,820,746.16 | 23,616,949.8 | 12,955,100.55 | 8,251,398.99 |
| 四、营业利润 | 183,627,386.63 | 158,267,273.66 | 6,603,683.47 | 47,965.97 |
| 加:营业外收入 | 27,704.55 | 119,191.52 | 194,975.99 | 84,654.36 |
| 减:营业外支出 | 18,789,313.76 | 12,671,274.84 | 1,602,380.06 | 935,706.71 |
| 五、利润总额 | 164,865,777.42 | 145,715,190.34 | 5,196,279.4 | -803,086.38 |
| 减:所得税费用 | 20,668,210.84 | 28,085,468.21 | 7,140,272.44 | 5,605,184.84 |
| 六、净利润 | 144,197,566.58 | 117,629,722.13 | -1,943,993.04 | -6,408,271.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 144,197,566.58 | 117,629,722.13 | -1,943,993.04 | -6,408,271.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 144,347,585.08 | 119,053,394.74 | -1,100,159.67 | -5,810,427.95 |
| 少数股东损益 | -150,018.5 | -1,423,672.61 | -843,833.37 | -597,843.27 |
| 扣除非经常损益后的净利润 | 153,350,597.72 | 90,300,205.84 | -24,400,092.83 | -21,591,317 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.36 | 0.3 | 0 | -0.01 |
| (二)稀释每股收益 | 0.36 | 0.3 | 0 | -0.01 |
| 九、综合收益总额 | 144,197,566.58 | 117,629,722.13 | -1,943,993.04 | -6,408,271.22 |
| 归属于母公司股东的综合收益总额 | 144,347,585.08 | 119,053,394.74 | -1,100,159.67 | -5,810,427.95 |
| 归属于少数股东的综合收益总额 | -150,018.5 | -1,423,672.61 | -843,833.37 | -597,843.27 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-23 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |